Table 4.

Results of a 6-arm factorials study of the acute treatment of migraine and TTH^a [33]

Measure	AAC-100	APAP + ASA	APAP	ASA	Caffeine	Placebo
PID @ 2 h (mm)	44.7	40.2	39.5	40.7	31.4	24.6
Active vs placebo	<0.0001	<0.0001	<0.0001	<0.0001	<0.02	–
Active vs AAC-100	–	0.002	0.02	0.003	<0.0001	<0.0001
Weighted SPID (%)	66.6	62.0	57.5	62.2	46.7	40.2
P vs placebo	<0.0001	<0.0001	<0.0001	<0.0001	0.0993	–
P vs AAC-100	–	0.02	0.07	0.0002	<0.0001	<0.0001
Functional disability @ 2 h (%)	53.9	49.4	48.6	48.4	39.4	30.5
P vs placebo	<0.0001	<0.0001	<0.0001	<0.0001	0.1491	–
P vs AAC-100	–	0.08	0.08	0.04	<0.0001	<0.0001
Global assessment of efficacy (%)	25.2	21.4	15.4	18.7	20.8	10.9
P vs placebo	<0.0001	<0.0001	<0.0001	<0.0001	0.0132	–
P vs AAC-100	–	0.01	<0.0001	0.009	<0.0001	<0.0001

AAC-100, acetaminophen 400 mg, aspirin 500 mg, caffeine 100 mg per 2-tablet dose; APAP + ASA, acetaminophen 400+ aspirin 500 mg per 2-tablet dose; APAP, acetaminophen 400 mg per 2-tablet dose; ASA, aspirin 500 mg per 2-tablet dose; caffeine, caffeine 100 mg per 2-tablet dose; PID, pain intensity difference from baseline; SPID, sum of pain intensity differences

^aThe study population included patients with migraine (84%) and TTH (13%) who typically treated attacks with non-prescription analgesics